Table 1 Mean zone of inhibition beyond well diameter (6 mm) produced on a range of clinically pathogenic microorganisms using a 5 mg/mL concentration of tested samples
Compound no. | Microorganisms | |||||
|---|---|---|---|---|---|---|
Fungi | Gram-Positive Bacteria | Gram-Negative Bacteria | ||||
AF | CA | SP | BS | PA | EC | |
3 | 16.2 | 12.5 | 16.8 | 14.6 | 12.1 | 12.8 |
4 | 15.7 | 13.2 | 10.5 | 13.6 | 12.6 | 11.2 |
10a | 12.6 | 11.2 | 0 | 0 | 0 | 0 |
10b | 17.3 | 16.9 | 17.3 | 18.3 | 18.3 | 22.6 |
11a | 21.2 | 19.6 | 23.8 | 23.8 | 17.3 | 19.9 |
11b | 15.7 | 13.3 | 0 | 0 | 0 | 0 |
12a | 18.9 | 15.4 | 15.7 | 14.1 | 10.8 | 11.1 |
12b | 16.7 | 18.1 | 16.7 | 21.1 | 10.7 | 9.9 |
13 | 19.1 | 16.9 | 13.6 | 14.7 | 12.1 | 10.4 |
14 | 15.7 | 14.1 | 17.2 | 14.9 | 15.2 | 17.2 |
15 | 16.4 | 12.7 | 19.9 | 18.4 | 11.6 | 10.9 |
20a | 20.8 | 16.8 | 13.1 | 10.8 | 13.4 | 12.3 |
20b | 26.8 | 15.3 | 11.2 | 12.7 | 9.8 | 11.3 |
20c | 15.9 | 17.1 | 18.7 | 15.4 | 11.7 | 10.3 |
20d | 20.6 | 15.8 | 18.9 | 12.7 | 11.3 | 9.9 |
21a | 17.7 | 18.2 | 19.2 | 15.4 | 10.2 | 8.8 |
21b | 19.1 | 18.9 | 17.3 | 17.7 | 0 | 9.9 |
22 | 23.8 | 32.4 | 13.2 | 13.3 | 0 | 10.2 |
23 | 18.8 | 15.6 | 17.9 | 13.3 | 11.4 | 10.7 |
25a | 18.4 | 16.3 | 12.6 | 13.2 | 10.1 | 10.9 |
25b | 0 | 0 | 12.7 | 14 | 9.7 | 8.3 |
Amphotericin B | 23.7 | 25.4 | – | – | – | – |
Ampicillin | – | – | 23.8 | 32.4 | – | – |
Gentamicin | – | – | – | – | 17.3 | 19.9 |